A comprehensive view of Valneva SE. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

French biotech Valneva, German drug maker IDT Biologika end COVID-19 vaccine deal as demand for vaccinations ebbs; IDT Biologika was to produce bulk vaccine in Germany for Valneva

Pfizer and Valneva to start late-stage clinical study of experimental VLA15 Lyme disease vaccination with 6,000 participants in US, northern Europe; in June, Pfizer invested US$92.3M in Valneva to support Lyme disease partnership

Pfizer investing US$95M in vaccine company Valneva SE; investment supports strategic partnership between both companies to develop Lyme disease vaccine

Valneva, Pfizer report positive Phase 2 pediatric data for VLA15 Lyme disease vaccine candidate; VLA15 is the only Lyme disease vaccine currently in clinical development, with Lyme disease affecting 476,000 people in US, 130,000 people in Europe annually

Valneva Scotland announces research funding of up to £20M from Scotland’s national economic development agency; initial grant of £12.5M supports development related to Valneva’s inactivated, whole virus COVID-19 vaccine candidate

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count